share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K:外國發行人報告
美股sec公告 ·  05/10 16:04
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a clinical-stage biotech company, has announced significant advancements in its proprietary MEAI-based synthetic alcohol beverage program. The company has completed most pre-clinical studies required for novel-food application submissions, which are recognized in multiple jurisdictions globally. Clearmind has secured patents for its alcohol substitute in the U.S., India, and Europe. The initiative is spearheaded by Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada. CEO Dr. Adi Zuloff-Shani highlighted the product's alignment with the growing trend towards no- and low-alcohol consumption and its potential health benefits. The no/low alcohol market, valued at over $13 billion in 2023, is expected to grow at a CAGR of +6% from 2023 to 2027. Clearmind aims to commercialize its compounds as regulated medicines, foods, or supplements and holds a portfolio of 27 granted patents across 18 patent families. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced significant advancements in its proprietary MEAI-based synthetic alcohol beverage program. The company has completed most pre-clinical studies required for novel-food application submissions, which are recognized in multiple jurisdictions globally. Clearmind has secured patents for its alcohol substitute in the U.S., India, and Europe. The initiative is spearheaded by Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada. CEO Dr. Adi Zuloff-Shani highlighted the product's alignment with the growing trend towards no- and low-alcohol consumption and its potential health benefits. The no/low alcohol market, valued at over $13 billion in 2023, is expected to grow at a CAGR of +6% from 2023 to 2027. Clearmind aims to commercialize its compounds as regulated medicines, foods, or supplements and holds a portfolio of 27 granted patents across 18 patent families. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
臨床階段的生物技術公司Clearmind Medicine Inc. 宣佈其基於MEAI的專有合成酒精飲料項目取得了重大進展。該公司已經完成了提交新食品申請所需的大多數臨床前研究,這些研究獲得了全球多個司法管轄區的認可。Clearmind 已在美國、印度和歐洲獲得其酒精替代品的專利。該計劃由加拿大紅牛和加拿大Juul Labs的前高管尼古拉斯·卡迪什牽頭。首席執行官阿迪·祖洛夫-沙尼博士強調,該產品符合無酒精和低酒精消費的增長趨勢及其潛在的健康益處。無酒精/低酒精市場在2023年價值超過130億美元,預計從2023年到2027年將以+6%的複合年增長率增長。Clearmind 的目標是將其化合物作爲受管制藥物、食品或補充劑進行商業化,並擁有 18 個專利家族的 27 項授權專利組合。該公司的股票在納斯達克和法蘭克福證券交易所上市,股票代碼分別爲 “CMND” 和 “CWY0”。
臨床階段的生物技術公司Clearmind Medicine Inc. 宣佈其基於MEAI的專有合成酒精飲料項目取得了重大進展。該公司已經完成了提交新食品申請所需的大多數臨床前研究,這些研究獲得了全球多個司法管轄區的認可。Clearmind 已在美國、印度和歐洲獲得其酒精替代品的專利。該計劃由加拿大紅牛和加拿大Juul Labs的前高管尼古拉斯·卡迪什牽頭。首席執行官阿迪·祖洛夫-沙尼博士強調,該產品符合無酒精和低酒精消費的增長趨勢及其潛在的健康益處。無酒精/低酒精市場在2023年價值超過130億美元,預計從2023年到2027年將以+6%的複合年增長率增長。Clearmind 的目標是將其化合物作爲受管制藥物、食品或補充劑進行商業化,並擁有 18 個專利家族的 27 項授權專利組合。該公司的股票在納斯達克和法蘭克福證券交易所上市,股票代碼分別爲 “CMND” 和 “CWY0”。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息